Abstract Library

#4667 Clinical outcomes in patients with typical (TC) and atypical bronchial carcinoids (AC): A 15-year retrospective study from an ENETS Center of Excellence

Introduction: Bronchial neuroendocrine neoplasms (NENs) can be subdivided into TCs, ACs and neuroendocrine carcinomas (NECs). Although a few studies have explored treatment approaches and oncological outcomes, most focus on surgical cohorts, small sample sizes, or mixed groups including TC, AC, and NECs. Real-life cohort data are lacking.

Conference:

Presenting Author: Clement D

Authors: Correia J, Sarker D, Dolly S, Frydman A, Srirajaskanthan R,

Keywords: bronchial carcinoid, treatment pattern, recurrence-free survival, overall survival,

#4638 Prognostic role of the kynurenine/tryptophan pathway and inflammatory cytokines in neuroendocrine tumour progression: A cross-sectional analysis

Introduction: Indoleamine-2,3-dioxygenase (IDO) converts L-tryptophan (T) to L-kynurenine (K) resulting in an immunosuppressive microenvironment.

Conference:

Presenting Author: Mancini C

Authors: Mancini C, Pecora G, Salerno G, Lionetto L, Visco V,

Keywords: Neuroendocrine Tumour, tryptophan, kynurenine, cytokines, immunotherapy, Indoleamine-2-3-dioxygenase,

#4531 The role of metabolism in neuroendocrine tumour cell models and patients

Introduction: It is recognised that the adipose tissue plays a major role in cancer through a metabolic coupling that supports tumour cell growth. Recent evidence suggests that altered metabolic pathways drive the development and influence the clinical outcomes of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Conference:

Presenting Author: Calabrese C

Authors: Calabrese C, Dellavalle S, Miserocchi G, Gabellone S, Spadazzi C,

Keywords: tumour metabolism, adipocytes, RNA-sequencing, GEP-NET,

#4502 Molecular analysis of non-functioning PanNETs of the alpha lineage reveals new subtypes and mechanisms of progression

Introduction: Most pancreatic neuroendocrine tumours (PanNETs) are non-functioning. Previously, we demonstrated that small, MEN1-only mutated α-like PanNETs can be distinguished from larger ADM (mutated in ATRX, DAXX and MEN1) PanNETs based on epigenetic profiles. ADM PanNETs have shorter disease-free survival and a higher relapse risk. However, their therapeutic responses vary, underscoring group heterogeneity. ADM PanNETs remain insufficiently characterised, with potential subtype-specific progression drivers with implications for treatment choice and clinical outcome.

Conference:

Presenting Author: Avanthay S

Authors: Avanthay S, Di Domenico A, Kirchner P, Bräutigam K, Chouchane A,

Keywords: pancreas, epigenetics, progression, metastasis, DAXX, ATRX, Pan NET,

#4456 Characteristics and clinical outcomes after endoscopic or surgical resection of localised sporadic type III gastric NETs: A national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network

Introduction: Type III gastric neuroendocrine tumours (gNETs) are rare indolent tumours with increasing incidence. Endoscopic resection has recently been described to be a safe strategy to remove small, localised type III gNETs.

Conference:

Presenting Author: Perrier M

Authors: Perrier M, Lefort R, Do Cao C, Hautefeuille V, Wallenhorst T,

Keywords: neuroendocrine neoplasm, stomach, endoscopy, surgery, carcinoid,